MA45442A - Dérivés de [1,2,3]triazolo[4,5-d]pyrimidine ayant une affinité pour le récepteur cannabinoïde de type 2 - Google Patents

Dérivés de [1,2,3]triazolo[4,5-d]pyrimidine ayant une affinité pour le récepteur cannabinoïde de type 2

Info

Publication number: MA45442A
Authority: MA; Morocco
Prior art keywords: triazolo; affinity; receptor type; pyrimidine derivatives; cannabinoid receptor
Prior art date: 2016-06-23

Application number

MA045442A

Other languages

English (en)

Inventor

Luca Gobbi

Uwe Grether

Wolfgang Guba

Adriaan Pieter Ijzerman

Julian Kretz

Rainer E Martin

Matthias Valentin Westphal

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-23

Filing date

2017-06-20

Publication date

2019-05-01

2017-06-20 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2019-05-01 Publication of MA45442A publication Critical patent/MA45442A/fr

Links

GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title 1
102000008906 Cannabinoid receptor type 2 Human genes 0.000 title 1
108050000860 Cannabinoid receptor type 2 Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Psychiatry (AREA)

MA045442A 2016-06-23 2017-06-20 Dérivés de [1,2,3]triazolo[4,5-d]pyrimidine ayant une affinité pour le récepteur cannabinoïde de type 2 MA45442A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16175924		2016-06-23

Publications (1)

Publication Number	Publication Date
MA45442A true MA45442A (fr)	2019-05-01

Family

ID=56203225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA045442A MA45442A (fr)	2016-06-23	2017-06-20	Dérivés de [1,2,3]triazolo[4,5-d]pyrimidine ayant une affinité pour le récepteur cannabinoïde de type 2

Country Status (24)

Country	Link
US (1)	US10457685B2 (fr)
EP (2)	EP3475282B1 (fr)
JP (2)	JP6962942B2 (fr)
KR (2)	KR102530131B1 (fr)
CN (4)	CN115093418A (fr)
AR (1)	AR108845A1 (fr)
AU (2)	AU2017283136C1 (fr)
BR (1)	BR112018075143A2 (fr)
CA (2)	CA3206921A1 (fr)
CL (1)	CL2018003610A1 (fr)
CO (1)	CO2018011231A2 (fr)
CR (2)	CR20180615A (fr)
IL (2)	IL292015B2 (fr)
MA (1)	MA45442A (fr)
MX (1)	MX2018014684A (fr)
MY (1)	MY197244A (fr)
PE (1)	PE20190109A1 (fr)
PH (1)	PH12018502733B1 (fr)
RU (1)	RU2741597C2 (fr)
SG (2)	SG10202113286RA (fr)
TW (2)	TWI824380B (fr)
UA (1)	UA123834C2 (fr)
WO (1)	WO2017220517A1 (fr)
ZA (1)	ZA201807133B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017220544A1 (fr)	2016-06-23	2017-12-28	F. Hoffmann-La Roche Ag	Nouveaux dérivés de [1,2,3]triazolo[4,5-d]pyrimidine
WO2017220516A1 (fr)	2016-06-23	2017-12-28	F. Hoffmann-La Roche Ag	Dérivés de triazolo[4,5-d]pyrimidine
CN109311886B (zh)	2016-06-23	2021-11-09	豪夫迈·罗氏有限公司	[1,2,3]三唑并[4,5-d]嘧啶衍生物
MX2023005713A (es) *	2020-11-23	2023-05-30	Hoffmann La Roche	Nuevo proceso para la elaboracion de derivados de tetrazol.
CN113387845B (zh) *	2021-07-16	2022-12-20	国药集团化学试剂有限公司	一种苯甲基磺酰氟的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2387138A1 (fr) *	1999-10-18	2001-04-26	University Of Connecticut	Derives indoliques cannabimimetiques
WO2006051704A1 (fr) *	2004-11-15	2006-05-18	Taisho Pharmaceutical Co., Ltd.	Composé imine
WO2006105217A2 (fr)	2005-03-31	2006-10-05	Schering Corporation	Antagonistes du recepteur de la thrombine spirocyclique
FR2887550A1 (fr)	2005-06-24	2006-12-29	Sanofi Aventis Sa	Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
WO2007120454A1 (fr) *	2006-03-30	2007-10-25	Irm Llc	Azolopyrimidines inhibitrices de l'activité du récepteur cannabinoïde 1
US8629157B2 (en) *	2009-01-05	2014-01-14	Boehringer Ingelheim International Gmbh	Pyrrolidine compounds which modulate the CB2 receptor
EP2311443A1 (fr)	2009-10-15	2011-04-20	Rheinische Friedrich-Wilhelms-Universität	Composition pharmaceutique contenant des antagonistes de récepteur de cannabinoïde-2
CN102924457A (zh) *	2011-08-12	2013-02-13	上海恒瑞医药有限公司	三唑并嘧啶类衍生物、其制备方法及其用途
UA111640C2 (uk)	2011-11-08	2016-05-25	Ф. Хоффманн-Ля Рош Аг	ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) *	2011-11-25	2015-06-30	Hoffmann-La Roche Inc.	[1,2,3]triazolo[4,5-D]pyrimidine derivatives
EA027935B1 (ru)	2013-03-07	2017-09-29	Ф. Хоффманн-Ля Рош Аг	Новые производные пиразола
HUE035333T2 (en)	2013-05-02	2018-05-02	Hoffmann La Roche	Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
CN105209466B (zh) *	2013-05-02	2018-05-18	豪夫迈·罗氏有限公司	作为cb2受体激动剂的嘌呤衍生物
PL3041843T3 (pl)	2013-09-06	2019-06-28	F. Hoffmann-La Roche Ag	Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2
AU2015341811A1 (en)	2014-11-07	2017-03-30	F. Hoffmann-La Roche Ag	Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
CN109311886B (zh)	2016-06-23	2021-11-09	豪夫迈·罗氏有限公司	[1,2,3]三唑并[4,5-d]嘧啶衍生物
WO2017220516A1 (fr)	2016-06-23	2017-12-28	F. Hoffmann-La Roche Ag	Dérivés de triazolo[4,5-d]pyrimidine
WO2017220544A1 (fr)	2016-06-23	2017-12-28	F. Hoffmann-La Roche Ag	Nouveaux dérivés de [1,2,3]triazolo[4,5-d]pyrimidine

2017
- 2017-06-20 MA MA045442A patent/MA45442A/fr unknown
- 2017-06-20 BR BR112018075143-0A patent/BR112018075143A2/pt not_active Application Discontinuation
- 2017-06-20 PH PH1/2018/502733A patent/PH12018502733B1/en unknown
- 2017-06-20 EP EP17731149.5A patent/EP3475282B1/fr active Active
- 2017-06-20 PE PE2018003112A patent/PE20190109A1/es unknown
- 2017-06-20 CR CR20180615A patent/CR20180615A/es unknown
- 2017-06-20 EP EP22174808.0A patent/EP4108665A1/fr not_active Withdrawn
- 2017-06-20 CR CR20220661A patent/CR20220661A/es unknown
- 2017-06-20 WO PCT/EP2017/064994 patent/WO2017220517A1/fr not_active Ceased
- 2017-06-20 AU AU2017283136A patent/AU2017283136C1/en not_active Ceased
- 2017-06-20 SG SG10202113286RA patent/SG10202113286RA/en unknown
- 2017-06-20 MX MX2018014684A patent/MX2018014684A/es unknown
- 2017-06-20 CA CA3206921A patent/CA3206921A1/fr active Pending
- 2017-06-20 CN CN202210807089.7A patent/CN115093418A/zh active Pending
- 2017-06-20 MY MYPI2018002797A patent/MY197244A/en unknown
- 2017-06-20 KR KR1020187037004A patent/KR102530131B1/ko active Active
- 2017-06-20 RU RU2018146657A patent/RU2741597C2/ru active
- 2017-06-20 UA UAA201900294A patent/UA123834C2/uk unknown
- 2017-06-20 SG SG11201809678VA patent/SG11201809678VA/en unknown
- 2017-06-20 JP JP2018566249A patent/JP6962942B2/ja not_active Expired - Fee Related
- 2017-06-20 IL IL292015A patent/IL292015B2/en unknown
- 2017-06-20 CN CN201780036295.XA patent/CN109348716A/zh active Pending
- 2017-06-20 CA CA3023043A patent/CA3023043A1/fr active Pending
- 2017-06-20 CN CN202210799583.3A patent/CN115073476A/zh active Pending
- 2017-06-20 CN CN202111184338.3A patent/CN113943297A/zh active Pending
- 2017-06-20 KR KR1020237014572A patent/KR20230062680A/ko active Pending
- 2017-06-21 AR ARP170101708A patent/AR108845A1/es unknown
- 2017-06-22 TW TW111101354A patent/TWI824380B/zh not_active IP Right Cessation
- 2017-06-22 TW TW106120830A patent/TWI764908B/zh not_active IP Right Cessation
2018
- 2018-10-19 CO CONC2018/0011231A patent/CO2018011231A2/es unknown
- 2018-10-25 ZA ZA2018/07133A patent/ZA201807133B/en unknown
- 2018-11-01 IL IL262711A patent/IL262711B2/en unknown
- 2018-12-14 CL CL2018003610A patent/CL2018003610A1/es unknown
- 2018-12-20 US US16/228,539 patent/US10457685B2/en active Active
2021
- 2021-07-26 AU AU2021206925A patent/AU2021206925B2/en not_active Ceased
- 2021-10-14 JP JP2021168709A patent/JP7308246B2/ja active Active

Also Published As

Publication number	Publication date
EP3475282C0 (fr)	2023-08-09
PH12018502733B1 (en)	2023-10-25
JP6962942B2 (ja)	2021-11-05
KR102530131B1 (ko)	2023-05-10
PE20190109A1 (es)	2019-01-15
AU2017283136C1 (en)	2021-07-29
CA3023043A1 (fr)	2017-12-28
US20190127384A1 (en)	2019-05-02
AU2021206925B2 (en)	2023-03-30
JP2022009140A (ja)	2022-01-14
CO2018011231A2 (es)	2019-02-08
IL292015A (en)	2022-06-01
RU2741597C2 (ru)	2021-01-27
US10457685B2 (en)	2019-10-29
SG10202113286RA (en)	2021-12-30
SG11201809678VA (en)	2018-11-29
IL292015B1 (en)	2024-03-01
EP4108665A1 (fr)	2022-12-28
CN115093418A (zh)	2022-09-23
AR108845A1 (es)	2018-10-03
TWI764908B (zh)	2022-05-21
EP3475282A1 (fr)	2019-05-01
CN109348716A (zh)	2019-02-15
AU2021206925A1 (en)	2021-08-19
KR20190019085A (ko)	2019-02-26
IL262711B1 (en)	2023-03-01
IL262711A (en)	2018-12-31
TWI824380B (zh)	2023-12-01
JP2019522648A (ja)	2019-08-15
BR112018075143A2 (pt)	2019-03-26
MY197244A (en)	2023-06-07
ZA201807133B (en)	2019-09-25
TW201811791A (zh)	2018-04-01
UA123834C2 (uk)	2021-06-09
CL2018003610A1 (es)	2019-03-29
AU2017283136B2 (en)	2021-04-29
CA3206921A1 (fr)	2017-12-28
MX2018014684A (es)	2019-02-28
RU2018146657A3 (fr)	2020-07-31
WO2017220517A1 (fr)	2017-12-28
IL292015B2 (en)	2024-07-01
CR20180615A (es)	2019-03-05
AU2017283136A1 (en)	2018-11-15
IL262711B2 (en)	2023-07-01
PH12018502733A1 (en)	2019-10-28
TW202216718A (zh)	2022-05-01
KR20230062680A (ko)	2023-05-09
RU2018146657A (ru)	2020-07-23
CR20220661A (es)	2023-02-21
EP3475282B1 (fr)	2023-08-09
CN113943297A (zh)	2022-01-18
JP7308246B2 (ja)	2023-07-13
CN115073476A (zh)	2022-09-20

Publication	Publication Date	Title
MA47500A (fr)	2019-12-25	Dérivés de pyrrolo [1,2-b]pyridazine
EP3980010A4 (fr)	2023-06-07	Composés de pyrazolo[1,5-a]pyrimidine 2,3,5-trisubstitués
EP3762385A4 (fr)	2021-11-24	L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
DK3478682T3 (da)	2021-09-13	[1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
CL2016003249A1 (es)	2017-07-14	(2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1’,2’:4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
EP3611174A4 (fr)	2020-09-09	Dérivé de [1,2,4] triazolo [1,5-c] pyrimidine en tant qu'inhibiteur du récepteur a2a
MA53675A (fr)	2021-11-17	Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
EP3380475A4 (fr)	2019-07-03	Dérivés d'octahydropyrrolo [3, 4-c
MA45442A (fr)	2019-05-01	Dérivés de [1,2,3]triazolo[4,5-d]pyrimidine ayant une affinité pour le récepteur cannabinoïde de type 2
EP3452481A4 (fr)	2020-02-26	Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux
DK3483163T3 (da)	2021-08-30	Triazolo[4,5-d]pyrimidinderivater som cb2-receptorantagonister
EP3660019C0 (fr)	2023-12-20	7h-pyrazolo[3,4-d]triazine-2-oxides en tant qu'explosifs
ZA201701814B (en)	2018-05-30	Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3596084A4 (fr)	2020-12-23	Composés 9,10,11,12-tétrahydro-8h-[1,4]diazépino[5',6':4,5]thiéno[3,2-f]quinolin-8-one et leurs utilisations
EP3508487A4 (fr)	2020-03-18	COMPOSÉ DE PYRAZOLO [1,5-a]PYRIMIDINE
EP3096762C0 (fr)	2023-06-28	Pyrazolo[1,5-a]pyrimidines comme composés antiviraux
IL260536B (en)	2020-10-29	6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
MA46690A (fr)	2019-09-11	Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP3551630A4 (fr)	2020-07-15	Dérivés d'imidazo [1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta
EP3679042A4 (fr)	2021-01-13	Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta
MA54960A (fr)	2021-12-22	Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine
DK3459953T3 (da)	2021-08-23	Hidtil ukendt 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-on-derivat
FR3042748B1 (fr)	2017-11-24	Siege pour vehicule ayant un mecanisme de limitation de coulissement
EP3903788A4 (fr)	2022-09-07	Composé macrocyclique de pyrazolo[1,5-a] pyrimidine
TH1501006629A (th)	2017-09-14	อนุพันธ์พีร์โรโล[2,3-d]ไพริมิดีนในฐานะอะกอนิสต์ของ CB2 รีเซปเตอร์